PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

Insys execs found guilty in Subsys kickback case

On Thursday, a federal jury convicted five former Insys Therapeutics executives, including the company's founder John Kapoor, for their involvement in bribing doctor...
Continue Reading →
News

Catalyst dives as FDA approves rival’s rare disease drug

The Food and Drug Administration has approved a rare disease drug from family-owned Jacobus Pharmaceutical, a decision that could present a competitive threat to Cat...
Continue Reading →
News

After investor attacks, Allergan’s reviewing ‘all options’—and this time it’s urgent, CEO says

Allergan shareholders last week voted against splitting the company's CEO and chairman roles, both currently held by Brent Saunders. (Allergan) Allergan Chairman...
Continue Reading →
News

McKesson settles state lawsuit for allegedly turning a blind eye to suspicious opioid sales

McKesson, without admitting liability or wrongdoing, has settled litigation with West Virginia that accused it lax supply chain oversight when it came to its lucrat...
Continue Reading →
News

Pfizer’s tafamidis wins blockbuster nod—and gets a lower price—to rival Alnylam, Ionis

Pfizer is pricing tafamidis drugs Vyndaqel and Vyndamax at $225,000 per year, lower than fellow ATTR rival meds by Ionis and Alnylam. (Vyndaqel) Once rejected by...
Continue Reading →
News

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (car...
Continue Reading →
News

Mr. Turhan Ozen, Chief Cargo Officer at Turkish Airlines, elected to the International Air Cargo Association (TIACA) Committee.

Turhan Ozen, serving as Chief Cargo Officer at the global brand Turkish Airlines, was elected to the International Air Cargo Association (TIACA) Committee, the joint...
Continue Reading →
News

Alexion, AstraZeneca secure backing of EMA panel for key drugs

Nine drugs received the backing of the European Union's drug review committee this month, setting them up for full approval in new or expanded indications within wee...
Continue Reading →
News

Watchdog sues FDA for dragging its feet on Parkinson’s drug warnings

Public Citizen is demanding the FDA heed its 2016 petition calling for a black box warning on six dopamine agonists tied to compromised impulse control. (Pixabay) ...
Continue Reading →
News

Lilly dumps phase 2 cancer drugs that survived previous cull

The drugs were among seven oncology programs Eli Lilly prioritized in summer 2017. (Eli Lilly) A pair of Eli Lilly’s cancer prospects that made it through a pipe...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026